Long noncoding RNA CCAT2 can predict metastasis and a poor prognosis: A meta-analysis.
Colon cancer associated transcript 2 (CCAT2), a novel long non-coding RNA (lncRNA), plays a key role in tumorigenesis. This meta-analysis systematically summarizes the relationship between CCAT2 and cancers. A comprehensive, computerized literature search was conducted in PubMed, Cochrane library, Chinese National Knowledge Infrastructure, and Chinese Wan Fang database. Odds ratios (ORs), hazard ratios (HRs) and their 95% confidence interval (95% CI) were calculated to assess the effect size. A total of 9 studies were enrolled in this meta-analysis, which was performed by Revman5.3 software and Stata12.0. Our meta-analysis indicates that patients with elevated expression of CCAT2 are prone to developing distant metastasis (DM) (OR=12.42; 95% CI=5.77-26.74; P < 0.00001), which is associated with a tendency for lymph nodes metastasis (LNM) (OR=3.60 95% CI=1.65-7.87, P=0.001). Further analyses reveal that patients with high CCAT2 expression have poorer overall survival (OS) (HR=1.53, 95% CI=1.15-2.02, P=0.003, random-effects) and progression-free survival (PFS) (HR=2.88, 95% CI=1.81-4.56, P < 0.00001, fixed-effects). Therefore, CCAT2 may be a potential novel biomarker for indicating clinical outcomes of human cancers.